Venable·IP / PATENT
PTAB Declares Four Halozyme PH20 Patents Unpatentable
On Sept. 25, 2026 the PTAB issued Final Written Decisions invalidating all remaining claims of Halozyme’s Keytruda Qlex patents, a setback that could widen competition for the drug.
ip-patentptab-decisionhalozymekeytrudapatent-invalidated
Read the original firm alert → Thursday, October 15, 2026